Andriole Vincent T
Yale University School of Medicine, New Haven, Connecticut 06520-8022, USA.
Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S113-9. doi: 10.1086/428051.
The quinolone class of antimicrobial agents has generated considerable interest since its discovery >40 years ago. Substantial progress has been made in our understanding of the molecular mechanisms of the action of quinolones against pathogenic bacteria, the induction of resistance to quinolones in these organisms, and the potential of each quinolone compound to induce toxicity in treated patients. Here, these key discoveries are reviewed; the present indications approved by regulatory agencies are described in detail, with comments on adverse events caused by quinolones in treated patients; and speculation about the future of the quinolones is proffered, even though their future is difficult to predict, because many factors may affect their clinical usefulness. However, the emergence of bacterial resistance to the quinolones is a major factor that will determine the future clinical effectiveness of these agents, so that intense investigation of mechanisms to either prevent or curtail resistance to quinolones is of prime importance to their future.
自40多年前发现以来,喹诺酮类抗菌剂引起了广泛关注。在我们对喹诺酮类药物针对病原菌的作用分子机制、这些生物体中对喹诺酮类药物耐药性的诱导以及每种喹诺酮化合物在治疗患者中诱导毒性的可能性的理解方面,已经取得了重大进展。在此,对这些关键发现进行综述;详细描述监管机构批准的当前适应症,并对喹诺酮类药物在治疗患者中引起的不良事件进行评论;尽管喹诺酮类药物的未来难以预测,因为许多因素可能影响其临床实用性,但仍对其未来进行了推测。然而,细菌对喹诺酮类药物耐药性的出现是决定这些药物未来临床疗效的一个主要因素,因此,深入研究预防或减少对喹诺酮类药物耐药性的机制对其未来至关重要。